Table 2 Comparison of AECOPD inpatients with and without IPA in the training set
Characteristic | No. (%)* | P | |
|---|---|---|---|
IPA (n = 59) | Non-IPA (n = 557) | ||
Age, years | |||
Median (range) | 72 (67, 82) | 76 (68, 84) | 0.08 |
Male gender | 55 (93.2) | 470 (84.4) | 0.69 |
Smoking index > 400 | 16 (27.1) | 97 (17.4) | 0.07 |
Comorbidities | |||
Previous tuberculosis | 6 (10.2) | 31 (5.6) | 0.15 |
Lung cancer | 4 (6.8) | 21 (3.8) | 0.29 |
Bronchiectasis | 1 (1.7) | 7 (1.3) | 0.78 |
Asthma | 1 (1.7) | 17 (3.1) | 0.56 |
Lobectomy surgery | 1 (1.7) | 12 (2.2) | 0.82 |
Other solid tumor | 0 (0) | 23 (4.1) | 0.11 |
Hypertension | 21 (35.6) | 276 (49.6) | 0.04 |
Diabetes mellitus | 7 (11.9) | 87 (15.6) | 0.44 |
Congestive heart failure | 13 (22) | 106 (19) | 0.57 |
Chronic and acute kidney disease | 4 (6.8) | 40 (7.2) | 0.96 |
Advanced liver disease | 2 (3.4) | 6 (1.1) | 0.14 |
Connective tissue disease | 0 (0) | 13 (2.3) | 0.24 |
Laboratory results | |||
Serum albumin < 30 g/L | 29 (49.2) | 122 (21.9) | < 0.01 |
GOLD III–IV | 56 (94.9) | 353 (63.4) | < 0.01 |
Respiratory failure | 13 (22) | 116 (20.8) | 0.83 |
Co-infection | |||
Lung bacterial infection | 10 (16.9) | 90 (16.2) | 0.88 |
Pulmonary tuberculosis | 0 (0) | 12 (2.2) | 0.25 |
Previous treatment | |||
Inhale corticosteroids | 11 (18.6) | 113 (20.3) | 0.76 |
Oral or intravenous corticosteroids | 18 (30.5) | 41 (7.4) | < 0.01 |
Cytotoxic drug utility | 0 (0) | 2 (0.4) | 0.64 |
Broad-spectrum antibiotic > 10 days | 17 (28.8) | 28 (5) | < 0.01 |
Invasive ventilator utility | 9 (15.3) | 40 (7.2) | 0.03 |
ICU admission 1 month prior | 10 (16.9) | 44 (7.9) | 0.02 |
Hospital acute exacerbation ≥ 2/year | 20 (33.9) | 91 (16.3) | < 0.01 |